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SYNTAX STUDY
INTRODUCTION                                                              
The treatment of symptomatic coronary artery disease has 
undergone major developmental changes in the last few decades.
Coronary artery bypass surgery has become a safe procedure 
with in-hospital mortality that averages 1% in low risk patients 
and between 2-5% in all risk patient groups.  New innovations 
like less invasive techniques (mini-bypass, off-pump surgery), 
arterial revascularisation, optimal cardio-protective measures, 
major advances in anaesthetic technique and improved peri-
operative care has improved outcomes after coronary bypass 
surgery.(9,15,16) 
Since the inception of PCI in 1977 by Gruentzig, the treatment of 
stenotic coronary artery disease has changed forever. The 
introduction of bare metal stents (BMS), then drug-eluting stents 
(DES) and new anti-platelet therapy has been the stimulus to treat 
more complex coronary artery lesions with percutaneous 
techniques.
Several studies of multi-vessel coronary disease have shown relative 
comparative mortality rates in both treatment groups, with only 
higher repeat revascularisation rates in the PCI groups. When 
refl ecting on these results the question arises if CABG is still the 
The SYNTAX (The Synergy between percutaneous coro-
nary intervention with TAXUS and cardiac surgery) study is 
an important study to indicate the best treatment option for 
patients who have three vessel coronary artery disease and/
or left main stem coronary disease (LMD). CABG (coronary 
artery bypass grafting) is still the preferred therapy for these 
patient groups with proven low mortality and excellent long 
term survival rates. PCI-DES (percutaneous coronary inter-
vention with drug eluting stents) is a relative non-invasive 
procedure with comparable short and medium term survival, 
but with a much higher repeat revascularisation rate. 
The SYNTAX Study enrolled 1800 patients in a randomised 
arm and 1275 in a registry arm. A SYNTAX Score was 
developed to assess the lesion morphology. At 12 months 
follow-up in the randomised group there was an increased 
death rate (4.3% vs 3.5%), myocardial infarction rate (4.8% vs 
3.2%) and repeat revascularisation rate (13.7% vs 5.9%) in 
the PCI-TAXUS (percutaneous coronary intervention with 
TAXUS stent) group compared to the CABG group. This 
trend continues up to 24 months with increased death rate 
(6.2% vs 4.9%), myocardial infarction rate (5.9% vs 3.3%), 
repeat procedure rate (17.4% vs 8.6%) and MACCE rate 
(23.4% vs 16.3%) in the PCI group  compared to the CABG 
group. 
The aim of the SYNTAX Study was to prove non-inferiority 
of PCI (percutaneous coronary intervention) compared to 
CABG in these patient populations. Non-inferiority of PCI-
TAXUS compared to CABG in this study population could 
not be shown at 12 or 24 months.
The cerebrovascular event rate was higher in the CABG 
group in both study arms (2.2% vs 0.6%) in the fi rst year,  but 
a nearly similar CVA rate during the next 12 months.
The study will terminate in 2011 and will give much-needed 
information regarding the optimal treatment option in 
patients with three vessel disease and/or left main disease.
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with three vessel disease and/or LMD. The SYNTAX Study is the 
most important comparative evidence-based study to determine 
the best treatment option for LM and three vessel disease.
CURRENT EVIDENCE FOR TREATMENT IN                    
MULTI-VESSEL CORONARY ARTERY DISEASE
Multiple randomised control trials comparing PCI and CABG in 
the last ± 20 years have failed to address the issue of LM and 
three vessel disease. Fifteen RCT including RITA, ERACI I, GABI, 
EAST, CABRI, MASS I, BARI, AWESOME, MASS II, ARTS I and 
SOS trials gave inconclusive results regarding this aspect.(1-8)
In summary all of these studies included only 35% of three vessel 
disease, 0% had LM disease, only 43% had proximal LAD (left 
anterior descending artery) disease, 100% had ejection fractions  of 
>50%, diabetes was only present in 16%. The studies exclude the 
bulk of patients that would benefi t from CABG (Table 1).
In the studies where BMS (bare metal stenting) was used, namely 
ERACI II, ARTS I, SOS and AWESOME the rate of repeat 
revascularisation was reduced signifi cantly, but was still high. In the 
SOS and ARTS I trial (67% - 72% 2VD; 0% LM) the repeat 
revascularisation was 30% (BMS) vs 9% (CABG) in the ARTS I 
trial and 21% (BMS) vs 6% (CABG) in the SOS trial. The com-
bined MACCE (death, MI, stroke, repeat revascularisation) was 
41.7% in the BMS group and 21.8% in the CABG group. In the 
5 year follow-up in the MASS II trial comparing CABG, PCI 
(BMS) and medical treatment groups, there was a 10 time higher 
incidence of repeat interventions in the PCI group in comparison 
with the CABG group (32.2% vs 3.5%). There was also a mild 
mortality difference over the 5 years favouring CABG (15.5% (PCI) 
VS 12.8% (CABG)). These studies tended to give a biased view 
with only a low percentage (4%) of screened patients being 
randomised. The trials excluded patients that would benefi t from 
bypass surgery i.e. those with three vessel disease, left main 
disease, patients with diabetes mellitus and those with impaired left 
ventricle function (<50%). Although these studies were not repre-
sentative of daily clinical practice, the results were generalised.(19)  
A search for “real world” evidence in registries developed from 
these highly selective patient trials. Hannan et al. published the 
3 year outcome of coronary artery bypass grafting vs stent 
TABLE 1:  Summary of 15 randomised control trials comparing PCI vs CABG in multivessel disease
A summary of the randomised trials comparing PCI and CABG. It shows the trial, the number of patients included in the trial, stents was implanted in only the last 5 trials.The next column shows 
the % of LMD included in each trial. The amount of patients with three vessel disease was low in the PCI group. The LV function was good in all of these patients. 
Use with permission from Prof DP Taggart: Presented at the Fall 2006 Annual Meeting of the Southern Thoracic Surgical Association (STSA).  Thomas B. Ferguson Lecture.
Trial No of Stent % Left main % 3VD Proximal  EF >50% % DM % IMA
 patients     LAD (%) 
RITA 1 011 - 0 12 - - 6 74
ERACI 127 - 0 45 - 100 11 75
LAUSANNE 134 - 0 0 100 - 12 100
GABI 359 - 0 18 - - 10 37
EAST 392 - 0 40 70 100 25 -
CABRI 1 054 - 0 40 - 100 12 75
MASS 142 - 0 - 100 100 21 100
BARI 1 829 - 0 41 36 100 24 80
TOULOSE 152 - 0 29 - - 14 58
SIMA 121 - 0 - 100 100 11 100
ERACI II 450 + 0 56 - - 17 88
AWESOME 454 + 0 45 - - - 70
MASS II 408 + 0 41
ARTS 1 205 + 0 32 - 100 19 93
SOS 988 + 0 38 45 100 14 81
Summary 8 826  0 35 41 100 16 79
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implantation in the New England Journal of Medicine of 26 May 
2005. The New York State Cardiac Surgery and Coronary 
Percutaneous Intervention database was used. Thirty seven 
thousand two hundred and twelve (37 212) patients with multi-
vessel disease underwent CABG and 22 102 patients underwent 
stenting between 1 January 1997 and 31 December 2000. Primary 
outcomes investigated were death and repeat revascularisation. 
In the CABG group 0.3% underwent re-CABG and 4.6% under-
went PCI in the 3 year time period. In the PCI group 7.8% under-
went CABG and 27.3% underwent repeated PCI. The observed 
rate of revascularisation in the CABG group was signifi cantly 
lower (p<0,001).
When comparing the PCI and CABG group there was a survival 
benefi t for CABG over the 3 years. There was a signifi cant survival 
benefi t in the group of patients who had three vessel disease and 
involvement of the proximal LAD (89.3% vs 84.4% survival when 
comparing CABG vs PCI over these 3 years).(9) 
This was an observational study and not a randomised control 
study and was therefore criticised by Flaherty. He concluded that 
there are major fl aws in the study and he emphasised that there 
was a risk-ascertainment bias between the two groups and therefore 
the difference in adjusted outcome in this study.(17)  
Very few of these patients received drug-eluting stents (DES). 
Hannan et al reviewed the same databases in New York State to 
evaluate the infl uence of DES and CABG on major adverse 
outcomes (death, myocardial infarction) or repeat revascularisa-
tion in a patient population from 1 October 2003 to 31 December 
2004. Those patients with previous revascularisation, main stem 
disease and those with recent myocardial infarctions were excluded. 
The study population included 9 963 DES patients and 7 437 
CABG patients. The outcomes up to 18 months after the initial 
procedure were reviewed.
It was a purely observational, non-randomised, retrospective study 
of a “real world” situation. The revascularisation rate in the 
CABG group was low with 0,1% of patients requiring repeat CABG 
and 5.1% in the PCI group receiving repeat procedures. In the 
DES group 2.2% required CABG and 28.4% required repeat PCI. 
In the three vessel and two vessel disease subgroup there was an 
adjusted long term survival benefi t in the CABG group (92.1% vs 
89.7% (DES); p<0,001). Comparing subgroups of patients with 
diabetes, left ventricle ejection fraction <40% and patient age >80 
years the conclusion was made that there was no mortality 
difference between the two groups but the rate of death or 
myocardial infarction was lower in the poor left ventricle function 
patients and in the patients >80 years that was treated with 
CABG.(10)
THE SYNTAX STUDY                                                    
(The synergy between percutaneous coronary intervention with 
TAXUS and cardiac surgery).
The SYNTAX Study is a phase III multi-centre, international, 
randomised controlled comparison of bypass surgery and PCI 
with a TAXUS drug eluting stent in 1800 patients. Included were 
patients with three vessel disease and/or left main stem coronary 
artery disease. Excluded from the study were patients with acute 
myocardial infarction, previous coronary intervention and those 
who required concomitant cardiac surgery.
The study design
Eighty fi ve centres (62 in Europe and 23 in the USA) enrolled 
patients for the trial.  One thousand eight hundred (1 800) patients 
were randomly assigned by a team of a local cardiac surgeon and 
an interventional cardiologist to undergo CABG or PCI with 
TAXUS stents in a 1:1 ratio. Patients were randomised only after 
both agreed that the patient can be treated by either interven-
tion (CABG or PCI).    
A non-inferiority comparison of the 2 groups was performed for 
the primary endpoints – a major cardiac or cerebrovascular event 
(death from any cause, stroke, myocardial infarction or repeat 
revascularisation).  Patients who did not qualify were entered into a 
separate parallel CABG or PCI registry.
All the angiograms were reviewed by an independent group of 
specialists in Rotterdam, Netherlands. A SYNTAX Score was 
calculated for these angiograms.
SYNTAX Score
The SYNTAX Score is an anatomical assessment score of an 
individual angiogram (Figure 1). It is an evaluation of coronary lesion 
complexity and a score is assigned to it. It includes multiple factors, 
eg. lesion calcifi cation, bi-or trifurcation lesions, left main or three-
vessel disease, thrombus, tortuosity, number and location of lesions. 
Scores are computer generated (www.syntaxscore.com).(13)
A score of ≤22:  Low Syntax Score
A score of 23-32:  Intermediate Score
A score of ≥33:  High Score
SYNTAX STUDY
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A scoring algorhythm has been developed that addresses the 
following twelve aspects: Coronary artery dominance; number of 
lesions; segments involved per lesion; total occlusion; trifurcation 
or bifurcation lesions; aorta-ostial lesions; severe tortuosity; lesion 
length >20 mm; heavy calcifi cation; thrombus; and diffuse disease/
small vessels. It is a self-guided questionnaire and a score is as-
signed to the information given.   
One thousand eight hundred (1 800) patients were recruited for 
the study in the randomised arm: 897 in the CABG group and 903 
in the TAXUS group (±28.5% D.M.). One thousand two hundred 
and seventy-fi ve (1 275) patients were included in the registry arm 
(CABG=1 077, PCI=198).
The primary clinical endpoint is the 1 and 2 year follow-up of 
major adverse cardiac and cerebral events (MACCE). The 24 
month follow-up has just been completed.  MACCE is defi ned as 
the all-cause death, myocardial infarction, any repeat revascularisa-
tion and cerebrovascular events. The study is ongoing and the study 
will terminate when 5 year follow-up has been completed. 
A non-inferiority comparison between the two therapeutic entities 
was done. A zone of non-inferiority was specifi ed between the 
differences of the MACCE rate of CABG vs PCI. The pre-specifi ed 
value was 6.6%. A value of less than 6.6% would suggest non-
inferiority for PCI compared to CABG. 
Randomised cohort of the SYNTAX Study
Demographics between the CABG and TAXUS groups were 
nearly similar. Twenty eight % of patients were diabetic and the 
Euroscore and Parsonnet scores were 3.8 and 8.4 respectively 
in both groups.
SYNTAX Score in the CABG group was 29.1 and 28.4 in the 
TAXUS group. Subgroups of left main (LM) disease and three 
vessel disease were identical in both groups (65% and 34%). 
In the TAXUS group a mean of 3.6 lesions was treated and 
4.6 stents was implanted/patient. Total length of stents implanted 
was 86.1 ± 47.9 mm and in 33.2% of patients stenting of >100 mm 
was performed.   
 
In the CABG group 15% of patients were off-pump cases, 97.3% 
received at least one arterial graft, 95.6% received an arterial graft 
to LAD, 27.6% received double arterial grafts (RIMA/LIMA). Only 
2.6% of patients received only venous grafts (Table 2). 
Primary endpoint for 12 month MACCE (The non-inferiority 
analysis):
Difference in MACCE = 8.3%, therefore the non-inferiority com-
parison was not met for the primary outcome at 12 months.(11)  
Subgroup MACCE rate: 
Non-inferiority was not proven in this randomised cohort, there-
fore information for each subgroup is of an observational nature 
and is hypothesis generating.
At 12 months there was an equivocal MACCE rate in the isolated 
left main group. In the LM+one vessel disease group there was 
an increase MACCE rate for CABG (13.2%) vs 7.5% for 
TAXUS. For LM+two vessel disease and LM+three vessel disease 
there was a preference for CABG. LM+two vessel disease: CABG=
14.4%, TAXUS=19.8%; LM+three vessel disease: CABG=15.4%, 
TAXUS=19.3%. For three vessel disease there was a better 
MACCE for CABG (11.5% vs 19.2% for TAXUS). In the diabetes 
group the MACCE rate was substantially higher in the TAXUS 
group than in the CABG group (CABG=14.2%, TAXUS=26.0%). 
At 24 months the MACCE rate in the three vessel disease sub-
group was 23.8% in the PCI group and 14.4% in the CABG group 
(p<0.001). In the left main subgroup the MACCE rate was 22.9% 
in the PCI group and 19.3% in the CABG group (p=0.27).   
FIGURE 1: Morphology of coronary artery segments for descrip-
tion in the SYNTAX Score (www.syntax.net)
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RESULTS IN THE PCI AND CABG REGISTRIES                
One hundred and ninety-eight (198) patients were enrolled in 
the PCI registry and 1 077 in the CABG registry. The CABG 
group had a higher SYNTAX Score than the PCI group and 
was therefore ineligible for PCI. The PCI group had a higher 
Euroscore, because of more co-morbidities (Table 3).(12)
DISCUSSION                                                                       
The SYNTAX Study is a landmark study in the treatment of 
three vessel and left mainstem coronary artery disease. The all-
comer design will make it possible to evaluate the proper treatment 
option for any given clinical situation. However it should be noted 
that 1 077 (35%) of all the patients screened (n = 3 075) were 
not eligible for PCI.  One hundred and ninety-eight (6.4%) patients 
were not suitable for CABG, due to a high logistic Euroscore. 
The higher MACCE for PCI in the randomised control cohort 
and registry was due to higher repeat procedures as well as 
higher myocardial infarction rates.  There was also a high incidence 
of staged procedures in the PCI group (14.1% in TAXUS RCT and 
13.0% PCI registry). The economic implications will be signifi cant. 
The myocardial infarction rate continues to rise in the PCI group, 
but stayed static in the CABG group (5.9% in PCI group com-
pared to 3.3% in the CABG group). This increase of myocardial 
infarction in the PCI group is most probably due to stent trom-
bosis as well as coronary territories not completely revascularised 
by PCI.  
Symptomatic graft closure/stent thrombosis in RCT was similar in 
the two groups at 12 months. (CABG = 3.4% vs TAXUS = 3.3%). 
Stent thrombosis is associated with a  higher incidence of malignant 
sequelae if compared to graft closure: the reported incidence of 
acute myocardial infarction is 65 – 70% and the mortality is 25 – 
45% post stent thrombosis. (JAMA 2005, 293: 2126-2130. Ann 
Int Med 2006; 144: 913 – 919; Circulation 2007; 15: 1440 – 5). 
The peri-procedure rate of myocardial infarction after CABG is 
SYNTAX STUDY
TABLE 2:  Results of the randomised cohort
*After 1 year the increase in CVA for CABG was 0.7% and 0.6% for TAXUS.   #After 1 year myocardial infarction rate increased by1.2% for TAXUS 0.1% for CABG(0.008).
+After 1 year the increase of repeat revascularisation was 3.7% for CABG and 5.6% for TAXUS (p=0.06).   ~After 1 year the increase in MACCE was 5.7% for CABG and 8.3% for TAXUS (p=0.03). 
 CABG TAXUS P-value CABG TAXUS P-value
All-cause death 3.5% 4.3% 0.37 4.9% 6.2% 0.53
CVA rate 2.2% 0.6% 0.003 2.8%* 1.4% 0.82
Myocardial infarction rate 3.2% 4.8% 0.11 3.3% 5.9% 0.01#
Symptomatic graft closure or 3.4% 3.3% 0.89
Stent trombosis   
Repeat revascularisation 5.9% 13.7% <0.0001 8.6% 17.4% <0.001+
MACCE(Myocardial infarction/ 12.1% 17.8% 0.0015 16.3% 23.4% <0.001~  
CVA/all-cause death/repeat 
revascularisation) 
 Twelve month results Twenty-four month results
TABLE 3:  Results for the PCI and CABG registries
 CABG TAXUS CABG TAXUS
 Twelve month  Twenty-four  
 results  month results
All-cause death 2.5% 7.3%  
Cerebrovascular 
accidents(CVA) 2.2% 0%  
Death / CVA / 
Myocardial infarction 6.6% 10.5%  
Repeat re-vascularisation 3.0% 12%  
Myocardial infarction 2.5% 4.2%  
Total MACCE 8.8% 20.4% 12.9% 28.6%
TABLE 4:  MACCE rates with reference to the SYNTAX score at 
24 months
 TAXUS CABG
Low SYNTAX  19.4% 17.4% P=0.63
score (0-22) 
Intermediate SYNTAX 22.8% 16.4%  P=0.06
score (23-32) 
High SYNTAX  28.2% 15.4% P=0.001
score (>32) 
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3-6%.  In patients with angiographic defi ned post-procedure graft 
closure and acute myocardial infarction the mortality is 9.3% if 
treated with PCI and 39% if treated with re-CABG.(18)  
A signifi cant difference in mortality and repeat procedure in 
especially the three vessel disease/LM+two vessel disease/
LM+three vessel disease groups favouring CABG. The reason for 
this increase in cardiac-related deaths in the PCI group is most 
probably due to the fact that CABG led to more complete 
revascularisation compared to PCI. This is more pronounced in 
the registry co-hort (CABG=2.5%, TAXUS=7.3%).  
An increased cerebrovascular event rate in the CABG group of 
1.6%. That amounts to a 3 times higher CVA rate in the CABG 
group. The CVA rate during the second 12 months shows an 
equivocal increase in both goups.
The SYNTAX score will be an important scoring system to 
decide on the best treatment option. In the CABG group the 
MACCE rate in all the SYNTAX Score levels was similar. (0 -22: 
14.7%;  23 -32: 12%;  ≥33: 10.9%), but MACCE events increased 
in the PCI group as the SYNTAX Score increased (0 - 22%: 13.6%; 
23-32: 16.9%;  ≥33: 23.4%). This is amplifi ed in the second year 
with a signifi cant increase in MACCE in the high SYNTAX Score 
PCI group. Therefore the higher the SYNTAX Score the higher 
the cardiac-related complications in the PCI  treated group.   
SYNTAX will therefore identify the best treatment option for the 
specifi c coronary pathology (SYNTAX Score).
Collaboration between surgeon and interventional cardiologist will 
be important in the future to optimise the best treatment option. 
Complexity of coronary artery anatomy, the patient’s risk for a 
specifi c procedure (Euroscore, Parsonnet) and the economic impli-
cations should be considered before embarking on a specifi c 
procedure.(14)
The 5 year follow-up will be completed in 2011 and will give us 
much-needed information about the ideal therapy for a specifi c 
coronary artery profi le.    
The treatment of complex coronary artery disease should ideally 
be managed by a team approach. The SYNTAX Study emphasises 
the benefi ts of surgery in this patient population at two year 
follow up. CABG is known to have good long term results and we 
need to determine if the same results can be achieved by stenting. 
At present CABG remains the preferred treatment for complex 
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